Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
drug development
CRO
FDA qualifies 1st AI drug development tool in MASH
AIM-NASH is meant to help score the different stages of liver biopsy, including fat infiltration, inflammation and scarring.
Gabrielle Masson
Dec 9, 2025 12:12pm
Value of AI biotechs nearly double that of peers: PitchBook
Nov 26, 2025 10:34am
Zealand pumps brakes on development of dual GLP-1/GLP-2 agonist
Nov 13, 2025 9:52am
Boehringer digs in on ADCs with $991M AimedBio licensing accord
Oct 15, 2025 10:05am
US biotechs thinking twice about licensing drugs to Europe
Sep 26, 2025 8:09am
Alternate history of NIH reveals potential impact of agency cuts
Sep 25, 2025 2:00pm
